id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC12943636 | core_pubmed_pmc | A Phase II Study of 177 Lu–Lilotomab Satetraxetan, a CD37 Antibody–Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients | A Phase II Study of 177 Lu–Lilotomab Satetraxetan, a CD37 Antibody–Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients Abstract Abstract Background : CD37, an antigen highly expressed in B-cell malignancies, served as the target in the LYMRIT-37-01 Part ... |
PMC5602538 | core_pubmed_pmc | Assessment of the Drug Interaction Potential of Unconjugated and GalNAc 3 -Conjugated 2′-MOE-ASOs | Assessment of the Drug Interaction Potential of Unconjugated and GalNAc 3 -Conjugated 2′-MOE-ASOs Abstract Antisense oligonucleotides are metabolized by nucleases and drug interactions with small drug molecules at either the cytochrome P450 (CYP) enzyme or transporter levels have not been observed to date. Herein, a co... |
PMC4947903 | core_pubmed_pmc | Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL | Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL Abstract Minimal residual disease (MRD) enables reliable assessment of risk in acute lymphoblastic leukemia (ALL). However, little is known on association between MRD status and germline g... |
PMC6444415 | core_pubmed_pmc | Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance | Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance Abstract Intentional drug overdoses with antidepressant and antipsychotic medications are an increasingly common problem. Currently, there is little guidance with regard to reintroduction of these medica... |
PMC6106189 | core_pubmed_pmc | Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies | Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies Abstract Abstract Three phase 1 pharmacokinetic (PK)/pharmacodynamics (PD) studies were conducted in healthy men and women to further characterize the safety, tolerability, and PK/PD of mirogabalin admi... |
PMC9065292 | core_pubmed_pmc | Single and Repeated Doses of EGb 761 ® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects | Single and Repeated Doses of EGb 761 ® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects Abstract The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761 ® alter the pharmacokinetics or pharmacodynamics of rivaroxa... |
PMC12093149 | core_pubmed_pmc | The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats | The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats Abstract ABSTRACT Sirolimus is a third‐generation immunosuppressant with multiple efficacies, including antifungal, antitumor, and immunosuppressive properties. We conducted a pharmacokinetic study t... |
PMC11815715 | core_pubmed_pmc | Mechanistic Evaluation of Anti‐CD19 CAR‐T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model | Mechanistic Evaluation of Anti‐CD19 CAR‐T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model Abstract ABSTRACT CAR‐T cell therapy, renowned for its success in oncology, is now venturing into the realm of B cell‐mediated autoimmune diseases. Recent observations have r... |
PMC9398147 | core_pubmed_pmc | Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors | Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors Abstract Abstract Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety... |
PMC7558337 | core_pubmed_pmc | Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice | Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice Abstract Non-invasive brain delivery of neurotherapeutics is challenging due to the blood-brain barrier. The revived interest in transferrin receptor antibodies (TfRMAbs) as brain drug-delivery vectors has revealed the ... |
PMC8452299 | core_pubmed_pmc | Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet | Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet Abstract Abstract A combination of olanzapine and samidorphan (OLZ/SAM) was recently approved by the US Food and Drug Administration f... |
PMC11511075 | core_pubmed_pmc | Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy | Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy Abstract Abstract Background/Objectives : Rivaroxaban and dabigatran are commonly used for thromboembolic disease management in active cancer patients. However, limited research explores the i... |
PMC7922365 | core_pubmed_pmc | Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model | Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model Abstract Abstract Efforts to develop and pair novel oral β-lactamase inhibitors with existing β-lactam agents to treat extended spectrum β-lactamase (ESBL) and carbapenemase-producing Ente... |
PMC11998985 | core_pubmed_pmc | Evaluation of Pharmacokinetics and Safety of the Biosimilar ( B01711 ) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study | Evaluation of Pharmacokinetics and Safety of the Biosimilar ( B01711 ) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study Abstract Abstract Objective B01711 is a biosimilar of insulin degludec/insulin aspart (IDegAsp 70/30)... |
PMC6407750 | core_pubmed_pmc | Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520 | Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520 Abstract Background BI 853520 is a potent inhibitor of focal adhesion kinase and is currently under clinical development for the treatment o... |
PMC7033381 | core_pubmed_pmc | Caffsim: simulation of plasma caffeine concentrations implemented as an R package and Web-applications | Caffsim: simulation of plasma caffeine concentrations implemented as an R package and Web-applications Abstract Caffeine is a naturally-occurring central nervous system stimulant found in plant constituents including coffee, cocoa beans, and tea leaves. Consumption of caffeine through imbibing caffeinated drinks is rap... |
PMC10697093 | core_pubmed_pmc | Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence | Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence Abstract Abstract The terminal complement C5 inhibitor ravulizumab was engineered from the humanized monoclonal antibody eculizumab to have an extended half-life and duration of action. It binds to human terminal complement protein C5, inhibiting its cl... |
PMC10055046 | core_pubmed_pmc | Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2 | Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2 Abstract A wide range of endogenous and xenobiotic organic ions require facilitated transport systems to cross the plasma membrane for their disposition 1 , 2 . In mammals, organic cation transporter subtypes 1 and 2 (OCT1 and OCT2, also known ... |
PMC9112936 | core_pubmed_pmc | Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization | Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization Abstract ABSTRACT The combination antimalarial therapy of artemisinin-naphthoquine (ART-NQ) was developed as a single-dose therapy, aiming to improve adherence relative to the mul... |
PMC11913088 | core_pubmed_pmc | Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study | Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study Abstract Abstract Context Somapacitan, a once-weekly reversible albumin-binding growth hormone (GH) derivative, is evaluated in short children born small for gestational age (SGA). Objective Evaluate effi... |
PMC6587565 | core_pubmed_pmc | Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus | Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus Abstract Abstract Aim To characterize the pharmacokinetic and pharmacodynamic properties of dasiglucagon, a novel, stable and liquid formulated glucagon analogue, during hypog... |
PMC6264041 | core_pubmed_pmc | Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report | Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report Abstract Abstract Background To our knowledge, no studies have evaluated the safety of carboplatin (CBDCA)-based chemotherapy in hemodialysis patients > ... |
PMC4243006 | core_pubmed_pmc | Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome | Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome Abstract Background and Objectives Morquio A syndrome (mucopolysaccharidosis IVA; MPS IVA) is a lysosomal storage disorder caused by deficiency of N -acetylgalactosamine-6-sulfatase, an e... |
PMC12249481 | core_pubmed_pmc | Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia | Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia Abstract In acute myeloid leukemia (AML) it is important to elucidate the biological events that lead from remission to relapse, which have a high probability of leading to an adverse disease outcome. The cancer stem cell mar... |
PMC12460062 | core_pubmed_pmc | Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential | Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential Abstract Abstract Ezetimibe is a cholesterol absorption inhibitor widely used in the treatment of dyslipidemia. However, its clinical efficacy is limited by poor aqueous solubility and low oral bioavailabili... |
PMC8378355 | core_pubmed_pmc | Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing Abstract Abstract Introduction Insulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration. Here we describe th... |
PMC12108383 | core_pubmed_pmc | Population Pharmacokinetics of Enrofloxacin in Micropterus salmoides Based on a Nonlinear Mixed Effect Model After Intravenous and Oral Administration | Population Pharmacokinetics of Enrofloxacin in Micropterus salmoides Based on a Nonlinear Mixed Effect Model After Intravenous and Oral Administration Abstract Simple Summary Population pharmacokinetics (PPK) is an interdiscipline of pharmacokinetics (PK) and statistics. It reflects the influence of fixed effects and s... |
PMC12404448 | core_pubmed_pmc | Phytochemical and pharmacoinformatics analysis of a traditional antipsoriatic oil formulation for its potential against proinflammatory cytokines TNF-α and IL-17A | Phytochemical and pharmacoinformatics analysis of a traditional antipsoriatic oil formulation for its potential against proinflammatory cytokines TNF-α and IL-17A Abstract Psoriasis, a persistent inflammatory condition with a complex origin, lacks a definitive cure despite the availability of diverse treatments. Vetpal... |
PMC8306322 | core_pubmed_pmc | Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? | Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? Abstract Abstract Beta-lactams are the most commonly prescribed antimicrobials in intensive care unit (ICU) settings and remain one of the safest antimicrobials prescribed. However, the misdiagnosis of beta-lactam-related adverse eve... |
PMC7300301 | core_pubmed_pmc | Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim | Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim Abstract Abstract Physiologically based pharmacokinetic (PBPK) models are increasingly used to support pediatric dose selection for small molecule drugs. In contrast, only a few pediatric PBPK models for therap... |
PMC12300238 | core_pubmed_pmc | Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women | Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women Abstract Abstract Pregnancy introduces significant physiological changes that alter the pharmacokinetics (PK) of antiretroviral therapy (ART), impacting its safety and efficacy in HIV-positive women. Optim... |
PMC7355497 | core_pubmed_pmc | Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine | Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine Abstract Abstract Herbal drugs are widely used for the auxiliary treatment of diseases. The pharmacokinetics of a drug may be altered when it is coadministered with herbal drugs that can affect drug absorption. The effects of herbal drugs... |
PMC7428950 | core_pubmed_pmc | Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS | Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS Abstract Abstract A sensitive and reliable ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the simultaneous determination of parecoxib and its meta... |
PMC9302693 | core_pubmed_pmc | Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy | Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy Abstract Abstract Aims Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need t... |
PMC6256190 | core_pubmed_pmc | Pharmacokinetics of 10-gingerol and 6-shogaol in the plasma of healthy subjects treated with red ginger ( Zingiber officinale var. Rubrum) suspension | Pharmacokinetics of 10-gingerol and 6-shogaol in the plasma of healthy subjects treated with red ginger ( Zingiber officinale var. Rubrum) suspension Abstract Abstract Red ginger ( Zingiber officinale var. Rubrum) is among the most widely consumed medicinal herbs in Indonesia. Ginger rhizome contains phenol compounds i... |
PMC10431051 | core_pubmed_pmc | Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy | Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy Abstract Abstract The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model‐inf... |
PMC2858163 | core_pubmed_pmc | Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin | Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Abstract OBJECTIVE Clinicians who treat children with type 1 diabetes often try to minimize the number of daily injections to reduce treatment burden and improve compliance. Despite the manufacturer's cautions against mixing glargi... |
PMC7571126 | core_pubmed_pmc | Identification of Antitumor Constituents in Toad Venom by Spectrum-Effect Relationship Analysis and Investigation on Its Pharmacologic Mechanism | Identification of Antitumor Constituents in Toad Venom by Spectrum-Effect Relationship Analysis and Investigation on Its Pharmacologic Mechanism Abstract (1) Background: Toad venom (Bufonis Venenum, known as ‘Chansu’ in Chinese), the secretion of the ear-side gland and skin gland of Bufo gargarizans cantor or Duttaphry... |
PMC11438743 | core_pubmed_pmc | High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy | High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy Abstract Background Colistin, administered as intravenous colistimethate (CMS), is still used in the critical care setting and current guidelines recommend high dosage CMS in patients undergoing continuous rena... |
PMC3212426 | core_pubmed_pmc | Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk | Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk Abstract Abstract The worldwide burden of cardiovascular disease is growing. In addition to lifestyle changes, pharmacologic agents that can modify cardiovascular disease processes have the potential to reduce ca... |
PMC5270295 | core_pubmed_pmc | Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial | Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial Abstract Abstract Evaluation of pharmacokinetic/pharmacodynamic (PK/PD) properties played an important role in the early clinical development of pembrolizumab. Because analysis of... |
PMC12375642 | core_pubmed_pmc | Chemotherapeutic nanoparticles for glioblastoma | Chemotherapeutic nanoparticles for glioblastoma Abstract Therapeutic agents into the brain are a major challenge for treatment of brain cancer due to the blood-brain barrier (BBB) that prevents many drugs from reaching the brain. The deadliest form of brain cancer is glioblastoma (GBM), and its current standard treatme... |
PMC10403678 | core_pubmed_pmc | Carrier-free nanoplatforms from natural plants for enhanced bioactivity | Carrier-free nanoplatforms from natural plants for enhanced bioactivity Abstract Highlights • Carrier-free nanoplatforms with self-assembly from natural plants. • Nano self-assembly of pure small molecules for enhanced bioactivity. • Extracellular vesicles containing active substances from fresh plants. • Charcoal nano... |
PMC12093347 | core_pubmed_pmc | Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers | Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers Abstract ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist,... |
PMC4151794 | core_pubmed_pmc | Targeted Nanogel Conjugate for Improved Stability and Cellular Permeability of Curcumin: Synthesis, Pharmacokinetics, and Tumor Growth Inhibition | Targeted Nanogel Conjugate for Improved Stability and Cellular Permeability of Curcumin: Synthesis, Pharmacokinetics, and Tumor Growth Inhibition Abstract Abstract Curcumin (CUR) is a unique natural compound with promising anticancer and anti-inflammatory activities. However, the therapeutic efficacy of curcumin was ch... |
PMC11602954 | core_pubmed_pmc | Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study | Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study Abstract Abstract Aims PTC518 is an orally administered, centrally and peripherally distributed huntingtin ( HTT ) pre‐mRNA splicing modifier being developed for the treatment of Huntington's disease (... |
PMC12072213 | core_pubmed_pmc | Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema | Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema Abstract ABSTRACT Hereditary angioedema (HAE) is a rare genetic disease that manifests as recurrent, unpredictable, and potentially life‐threatening attacks of angioedem... |
PMC12823945 | core_pubmed_pmc | In vitro design of intrathecal drug administration therapies | In vitro design of intrathecal drug administration therapies Abstract Due to the scarcity of reliable in vivo data, the pharmacokinetics of intrathecally (IT) administered drugs remain inadequately quantified. Designing new therapies is further hindered by variability in experimental methods, inter-individual and inter... |
PMC6011315 | core_pubmed_pmc | In vitro and in vivo evaluation of hypothermia on pharmacokinetics and pharmacodynamics of nimodipine in rabbits | In vitro and in vivo evaluation of hypothermia on pharmacokinetics and pharmacodynamics of nimodipine in rabbits Abstract Abstract Objective To investigate the effect of hypothermia on the pharmacokinetics and pharmacodynamics of nimodipine in rabbits using in vivo and in vitro methods. Methods Five healthy New Zealand... |
PMC4131383 | core_pubmed_pmc | Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics | Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics Abstract Abstract Aim: The research traces development of nanovesicles to attain enhanced transdermal delivery of felodipine and also investigates parameters for optimization of variable membrane compositions contai... |
PMC9312263 | core_pubmed_pmc | Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’ | Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’ Abstract Abstract The surge in antimicrobial resistance and the limited availability of new antimicrobial drugs has fueled the interest in optimizing antibiotic dosing. An ideal dosing regimen leads to maximal bacterial ce... |
PMC9207242 | core_pubmed_pmc | Population Pharmacokinetics of Vancomycin in Pregnant Women | Population Pharmacokinetics of Vancomycin in Pregnant Women Abstract Abstract Objective: Vancomycin is a glycopeptide antibacterial indicated for serious gram-positive infections. Pharmacokinetics (PK) of vancomycin have not been described in pregnant women. This study aims to characterize the PK disposition of vancomy... |
PMC7575488 | core_pubmed_pmc | Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer | Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer Abstract Summary LY3023414 is an oral, selective adenosine triphosphate-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms, mammalian target of rapamycin, and DNA-protein kinase in clinical de... |
PMC12415655 | core_pubmed_pmc | Comparison of In Vitro and In Vivo Dissolution of Norvir ® Oral Powder: In Vivo Relevance of a too Rapid In Vitro Dissolution Test | Comparison of In Vitro and In Vivo Dissolution of Norvir ® Oral Powder: In Vivo Relevance of a too Rapid In Vitro Dissolution Test Abstract Abstract Objectives Norvir ® oral powder [ritonavir (RTV)] employs polyvinylpyrrolidone/vinyl acetate as the polymer to formulate an amorphous solid dispersion. Its oral absolute b... |
PMC8217983 | core_pubmed_pmc | Optimal control for colistin dosage selection | Optimal control for colistin dosage selection Abstract Abstract Optimization of antibiotic administration helps minimizing cases of bacterial resistance. Dosages are often selected by trial and error using a pharmacokinetic (PK) model. However, this is limited to the range of tested dosages, restraining possible treatm... |
PMC12358308 | core_pubmed_pmc | Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults | Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults Abstract ABSTRACT Rimegepant is a small‐molecule calcitonin gene‐related peptide receptor antagonist approved for acute and preventive migraine treatment in adults, administered as an orally disinteg... |
PMC6629781 | core_pubmed_pmc | Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets | Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets Abstract Enalapril is recommended as the first line of therapy and is proven to improve survival rates for treatment of Pediatric Heart... |
PMC11335556 | core_pubmed_pmc | The effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes | The effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes Abstract Abstract Introduction Pregnancy results in significant changes in drug pharmacokinetics (PK). While previous studies have elucidated the impact of pregnancy-related hormones (PRH) on mRNA or protein e... |
PMC10215896 | core_pubmed_pmc | Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones | Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones Abstract Abstract The consequences of non-adherence to treatment (NAT) on antimicrobial efficacy may depend on drug forgiveness—a property that should account for pharmacokinet... |
PMC8538818 | core_pubmed_pmc | Pharmacokinetic/Pharmacodynamic Modeling of Spiramycin against Mycoplasma synoviae in Chickens | Pharmacokinetic/Pharmacodynamic Modeling of Spiramycin against Mycoplasma synoviae in Chickens Abstract This research aimed to assess the pharmacokinetics/pharmacodynamics (PK/PD) and tissue residues of spiramycin in chickens. The PK of spiramycin were determined in 12 chickens using a parallel study design in which ea... |
PMC6790214 | core_pubmed_pmc | Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function | Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function Abstract Abstract Purpose Revefenacin, a long-acting muscarinic antagonist for nebulization, has been shown to improve lung function in patients with chronic obstructive pulmonary disease. Here we report pharmacokinetic (PK) ... |
PMC6804264 | core_pubmed_pmc | Enlarged Pore Size Chiral Mesoporous Silica Nanoparticles Loaded Poorly Water-Soluble Drug Perform Superior Delivery Effect | Enlarged Pore Size Chiral Mesoporous Silica Nanoparticles Loaded Poorly Water-Soluble Drug Perform Superior Delivery Effect Abstract Abstract Large mesopores of chiral silica nanoparticles applied as drug carrier are worth studying. In this study, chiral mesoporous silica nanoparticles (CMSN) and enlarged chiral mesopo... |
PMC12325061 | core_pubmed_pmc | Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors | Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors Abstract Abstract The document comprehensively reviews proton pump inhibitors (PPIs), focusing on their pharmacodynamics, pharmacokinetics, drug interactions, toxicity, and clinical efficacy.... |
PMC6150614 | core_pubmed_pmc | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach Abstract ABSTRACT The linear pharmacokinetics (PK) of therapeutic mono... |
PMC6447877 | core_pubmed_pmc | Administration of Vancomycin at High Doses in Patients with Post Neurosurgical Meningitis: A Comprehensive Comparison between Continuous Infusion and Intermittent Infusion | Administration of Vancomycin at High Doses in Patients with Post Neurosurgical Meningitis: A Comprehensive Comparison between Continuous Infusion and Intermittent Infusion Abstract Abstract Poor penetration of vancomycin into Central Nervous System (CNS) can lead to treatment failure. The aim of this study was to evalu... |
PMC9343077 | core_pubmed_pmc | Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice | Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice Abstract Due to the rapid spread of coronavirus disease 2019 (COVID-19), there is an urgent requirement for the development of additional diagnostic tools for further analysis of the disease. The isolated nanobody... |
PMC10176008 | core_pubmed_pmc | Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects | Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects Abstract Abstract Gonorrhea is a sexually transmitted infection for which antibiotic treatment options have declined due to increasing antibiotic resistance. Zoliflodac... |
PMC7531504 | core_pubmed_pmc | Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study | Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study Abstract Supplemental Digital Content is available in the text. Keywords: antidepressant, fast onset of action, intravenous administration, major depressive disorde... |
PMC8666898 | core_pubmed_pmc | Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival | Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival Abstract Background Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppres... |
PMC8471455 | core_pubmed_pmc | Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat | Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat Abstract Abstract One of the main obstacles in neurological disease treatment is the presence of the blood–brain barrier. New predictive high-throughput screening tools are essential to avoid costly failures in the advanced... |
PMC2872834 | core_pubmed_pmc | Titration of the plasma effect site equilibrium rate constant of propofol; a link method of 'Concentration-Probability-Time' | Titration of the plasma effect site equilibrium rate constant of propofol; a link method of 'Concentration-Probability-Time' Abstract Abstract Background The plasma effect-site equilibrium rate constant (k e0 ) of propofol has been reported in various pharmacodynamic studies; however, it is not desirable to apply k e0 ... |
PMC8524809 | core_pubmed_pmc | The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies | The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies Abstract Abstract Small molecule inhibitors have previously been investigated in different studies as possible therapeutics in the treatment of severe acute respiratory syndrome coronavirus-... |
PMC3284452 | core_pubmed_pmc | Decreased defluorination using the novel beta-cell imaging agent [ 18 F]FE-DTBZ-d4 in pigs examined by PET | Decreased defluorination using the novel beta-cell imaging agent [ 18 F]FE-DTBZ-d4 in pigs examined by PET Abstract Background Fluorine-18 dihydrotetrabenazine [DTBZ] analogues, which selectively target the vesicular monoamine transporter 2 [VMAT2], have been extensively studied for in vivo quantification of beta cell ... |
PMC11425259 | core_pubmed_pmc | AI‐Powered Mining of Highly Customized and Superior ESIPT‐Based Fluorescent Probes | AI‐Powered Mining of Highly Customized and Superior ESIPT‐Based Fluorescent Probes Abstract Abstract Excited‐state intramolecular proton transfer (ESIPT) has attracted great attention in fluorescent sensors and luminescent materials due to its unique photobiological and photochemical features. However, the current stru... |
PMC4355445 | core_pubmed_pmc | Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery | Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery Abstract Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operate... |
PMC3102212 | core_pubmed_pmc | A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies | A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies Abstract Purpose UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to d... |
PMC6989242 | core_pubmed_pmc | Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects | Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects Abstract Proton-pump inhibitors (PPIs) are effectively used to treat acid-related diseases, including gastroesophageal reflux disease (GERD); however, many unmet medical needs still exist. As a new treatment... |
PMC12482220 | core_pubmed_pmc | Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma | Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma Abstract Background Zevorcabtagene autoleucel (zevor-cel) is a fully human autologous CAR T-cell therapy targeting B-cell maturation antigen approved in China since 2024 fo... |
PMC11787712 | core_pubmed_pmc | Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) | Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) Abstract Summary Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral... |
PMC6534834 | core_pubmed_pmc | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition Abstract Background The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification.... |
PMC8257990 | core_pubmed_pmc | Morphine and fentanyl exposure during therapeutic hypothermia does not impair neurodevelopment | Morphine and fentanyl exposure during therapeutic hypothermia does not impair neurodevelopment Abstract Abstract Background Hypothermia-treated and intubated infants with moderate or severe hypoxic-ischemic encephalopathy (HIE) usually receive morphine for sedation and analgesia (SA) during therapeutic hypothermia (TH)... |
PMC6706704 | core_pubmed_pmc | Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma | Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma Abstract Iguratimod is a new synthetic disease-modifying antirheumatic drug intended to treat patients with rheumatoid arthritis. A new method using recombinant human CYP450s yeast cells contain... |
PMC9899833 | core_pubmed_pmc | Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics | Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics Abstract Objective: FCN-159 is a highly active mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibit... |
PMC8488777 | core_pubmed_pmc | A Phase I, First‐in‐Human Study of GSK2849330 , an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors | A Phase I, First‐in‐Human Study of GSK2849330 , an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors Abstract Abstract Background GSK2849330, an anti‐HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signaling in cancer cells, is engineered for enhanced antibody‐dependent cellular cytotoxicity ... |
PMC10725275 | core_pubmed_pmc | Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody | Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody Abstract Abstract We sought to characterize the population pharmacokinetic/pharmacodynamic (PK/PD) relationship of bococizumab (... |
PMC10485820 | core_pubmed_pmc | Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model | Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model Abstract Highlights • Dose decision of HSK7653 tablets in clinical trial of specific populations was determined according to the PBPK model prediction results.... |
PMC4021671 | core_pubmed_pmc | Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits | Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits Abstract Abstract Purpose To compare the pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide (TA) in rabbits. Methods The rabbits received intravitreal injections of 4 mg ... |
PMC12680532 | core_pubmed_pmc | Long-acting management of diabetes and associated complications using an injectable thermosensitive hydrogel incorporating IgG-conjugated GLP-1RA | Long-acting management of diabetes and associated complications using an injectable thermosensitive hydrogel incorporating IgG-conjugated GLP-1RA Abstract Abstract Rationale : The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has advanced diabetes management. Nevertheless, frequent administration re... |
PMC10717358 | core_pubmed_pmc | Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions | Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions Abstract Background Patients with chronic kidney disease (CKD) are at high risk of drug-related problems (DRPs) because of extensive comorbidities and pharmacokinetic changes. This study aimed to identify D... |
PMC12221999 | core_pubmed_pmc | Population PK and Exposure‐Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | Population PK and Exposure‐Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma Abstract ABSTRACT Zolbetuximab is a chimeric (mouse/human) monoclonal antibody directed against the tight junction protein claudin 18.2, which is highly expressed in gastric/gas... |
PMC5487625 | core_pubmed_pmc | Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis | Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis Abstract ABSTRACT Variable exposure to antituberculosis (TB) drugs, partially driven by genetic factors, may be associated with poor clinical outcomes. Previous studies have suggested an influence of the S... |
PMC6590359 | core_pubmed_pmc | Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Abstract Abstract Tolvaptan is the first approved drug treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPK... |
PMC4364559 | core_pubmed_pmc | Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers | Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers Abstract Abstract Context Bitter taste, as well as dissolve time, presents a significant challenge for the acceptability of formulations for oral transmucosal drug delivery. Objectiv... |
PMC10112192 | core_pubmed_pmc | Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects | Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects Abstract ABSTRACT Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is a novel oral carbapenem prodrug being develo... |
PMC8460463 | core_pubmed_pmc | Ustekinumab pharmacokinetics after subcutaneous administration in swine model | Ustekinumab pharmacokinetics after subcutaneous administration in swine model Abstract Background Due to multiple similarities in the structure and physiology of human and pig skin, the pig model is extremely useful for biological drug testing after subcutaneous administration. Knowledge of the differences between subc... |
PMC4579250 | core_pubmed_pmc | Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update | Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update Abstract A prolonged QT interval is an important risk factor for ventricular arrhythmias and sudden cardiac death. QT prolongation can be caused by drugs. There are multiple risk factors for drug-induced QT prolongation, including genetic variation. Q... |
PMC7647766 | core_pubmed_pmc | LC-MS/MS Method for Rapid Quantification of Progesterone in Rabbit Plasma and Its Application in a Pharmacokinetic Study of the Transdermal Formulation | LC-MS/MS Method for Rapid Quantification of Progesterone in Rabbit Plasma and Its Application in a Pharmacokinetic Study of the Transdermal Formulation Abstract Abstract A rapid and effective method using QuEChERS-based sample preparation procedure and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis ... |
PMC11815413 | core_pubmed_pmc | TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial | TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial Abstract Abstract Background M6223 is an intravenous (IV), Fc-competent, fully human, antagonistic, anti-T cell immunoreceptor with immunoglobulin and immu... |
PMC3065843 | core_pubmed_pmc | A Novel Domperidone Hydrogel: Preparation, Characterization, Pharmacokinetic, and Pharmacodynamic Properties | A Novel Domperidone Hydrogel: Preparation, Characterization, Pharmacokinetic, and Pharmacodynamic Properties Abstract Abstract The purpose of the present study was to prepare a novel domperidone hydrogel. The domperidone dispersion was prepared by the solvent evaporation method. The characteristics of domperidone dispe... |
PMC3801461 | core_pubmed_pmc | Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics? | Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics? Abstract Abstract Background: A recent meta-analysis based on data from > 7,000 pregnancies reported an association between prenatal polychlorinated biphenyl (PCB)–153 exposure and reduced birth weight.... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.